Xconomy National

Archives

by in
Entry Author Date Location
Celgene Buys Avila for $350M, Gaining Promising “Covalent” Drugs Arlene Weintraub 01/26/12 Boston
(Mis)Understanding Drug Discovery: It’s Much Harder Than Rocket Science Stewart Lyman 09/07/11 Seattle
Sanofi Collaboration Drives Regeneron’s Transformation From R&D House to Commercial Player Arlene Weintraub 07/13/11 New York
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News Luke Timmerman 06/23/11 Seattle
Pfizer Adds to Data on Novel RA Drug Arlene Weintraub 04/28/11 New York
BG Medicine Chief Speaks on Rough IPO Climate, (Finally) Going Public Ryan McBride 04/21/11 Boston
Pfizer Releases Top Line Data on Novel RA Drug Arlene Weintraub 04/15/11 New York
Targeted Genetics, Re-invented as AmpliPhi, Bets on Anti-Bacterials, Moves HQ to London Luke Timmerman 03/09/11 Seattle
Diagnostics Are Warming Up in Era of Fast, Cheap Sequencing, Says MDV’s Rowan Chapman Luke Timmerman 02/07/11 San Francisco
Acceleron Pharma Cuts 40 Percent of Workforce Luke Timmerman 11/03/10 Boston
Via Science Forms to Launch “Big Data” Analytics Startups Ryan McBride 11/02/10 Boston
Montgomery Joins Alder Board Luke Timmerman 11/01/10 Seattle
Amylin Regroups From FDA Smackdown, CalciMedica Plans Trial of New Anti-Immune Drug, FDA Gives CareFusion Recall Highest Priority, & More San Diego Life Science News Bruce V. Bigelow 10/21/10 San Diego
CalciMedica Charges Ahead Toward First Human Test of Oral Pill for Psoriasis Luke Timmerman 10/20/10 San Diego
Rigel Nabs $25M From AstraZeneca Luke Timmerman 09/29/10 San Francisco
Rigel Arthritis Drug Passes Trial Luke Timmerman 09/23/10 San Francisco
Cytomx, Backed by Third Rock & Roche, Raises $30M for New Class of Antibodies Luke Timmerman 09/23/10 San Francisco
Glaxo’s Tempero Pharma Advances on Hot Niche of Immunology Ryan McBride 07/15/10 Boston
Femta Pharmaceuticals Snags $2.2M for Potent Antibody Drugs Luke Timmerman 07/13/10 San Diego
Gilead Buys CGI for Up To $120M Luke Timmerman 06/25/10 San Francisco
Pfizer Dumps Trubion’s Lead Rheumatoid Arthritis Drug, Keeps Next-Gen Product Alive Luke Timmerman 06/14/10 Seattle
Biotech Drug Discovery in Seattle: A Look Back Stewart Lyman 06/11/10 Seattle
Alder, Bristol Arthritis Drug Shows “Outstanding” Results in Trial, Lead Researcher Says Luke Timmerman 05/17/10 Seattle
Alder Seeks to Treat Cancer in a Radical Way, Fighting Inflammation, Not Tumors Luke Timmerman 05/13/10 Seattle
Lycera Keeps Its Investors Happy, Snags $11M to Pursue New Autoimmune Drugs Luke Timmerman 04/28/10 Detroit
Innovation Northwest Wrapup: Alder, Tekmira, Acucela, & Other Emerging Little Biotechs Luke Timmerman 03/19/10 Seattle
Sage Bionetworks Strikes Deal With Pfizer to Find Cancer Drug Targets Luke Timmerman 01/11/10 Seattle
Alder Rival Wins FDA Approval Luke Timmerman 01/09/10 Seattle
Lycera, a Midwestern Biotech Star, Moves Head Office to Boston, Hires Biogen Vet as CEO Luke Timmerman 01/07/10 Boston
Alder Rises From Ashes of Layoffs to Become Seattle Biotech Force Luke Timmerman 01/04/10 Seattle
Page 1 of 3 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.